Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
Phase 3 trial finds oral microbiome therapy cuts risk of recurrent C diff
In a phase 3 trial, an investigational oral microbiome therapy was superior to placebo in reducing the risk of recurrent Clostridioides difficile infection, researchers reported yesterday in the New England Journal of Medicine.